In this study, we aim (1) to validate the clinical relevance of CDX2 in a large group of CRC patients (n = 637), (2) to determine whether epigenetic modifications contribute to CDX2 repression, and (3) to restore CDX2 expression in vitro by targeting methylation and histone deacetylation. The gene discussed is CDX2; the disease is colorectal carcinoma.